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Primary central nervous system germ cell tumours (CNS GCTs) are
relatively rare and make up less than 3% of all brain tumours.
Because of the rarity of CNS GCTs, published series usually
combine both germinoma and non-germinomatous intracranial
germ cell tumours. Germinoma is a specific entity, however, and
deserves special consideration in terms of management. At least half
to two-thirds of CNS GCTs are germinomas. Like its counterpart in
the testis, this tumour is one of the most radiosensitive. Intracranial
germinoma can be cured with radiotherapy; event-free and overall
survival using standard craniospinal radiotherapy ranges between 70
and 95% (Sung et al, 1978; Linstadt et al, 1988; Shibamoto et al,
1988; Dearnaley et al, 1990). Despite this high cure rate, the treat-
ment of germinoma has generated much interest and given rise to
extensive controversies in recent years. Despite its effectiveness,
craniospinal radiotherapy is responsible for late effects such as
cognitive dysfunction, vascular pathology, endocrinopathy, spinal
growth impairment and leukoencephalopathy (Darendeliler et al,
1990; Clayton et al, 1991; Mulhern et al, 1992).
It has been shown that, like seminoma of the testis or dysgermi-
noma of the ovary, intracranial germinomas are also chemosensi-
tive. Using systemic chemotherapy, promising response rates have
been achieved in newly diagnosed and relapsing patients with
cyclophosphamide (Allen et al, 1987) or cisplatin-based regimens
(Kobayashi, 1989; Patel et al, 1992). Consequently, new treatment
strategies have been developed to use primary chemotherapy to
avoid or to reduce radiotherapy in good responders. In 1990, The
Soci￿t￿ Fran￿aise d￿Oncologie P￿diatrique (SFOP) initiated a
multicentre study to replace prophylactic craniospinal radio-
therapy with systemic chemotherapy and to restrict radiotherapy to
a focal boost of 40 Gy to the initial tumour volume in children
with non-metastatic germinomas. Children with metastatic germi-
nomas were allocated to receive chemotherapy and low-dose
craniospinal radiotherapy. This paper reports the results of this
strategy in 57 patients with intracranial germinomas treated
between January 1990 and December 1996.
PATIENTS AND METHODS
The pathological diagnosis of germinoma was required before initi-
ation of the protocol. Patients with alpha-fetoprotein (aFP) and/or
human chorionic gonadotrophin (HCG) and/or beta human chori-
onic gonadotrophin (bHCG) secretion were treated according to
the SFOP protocol for intracranial secreting germ tumours.
However, patients with moderate secretion of bHCG (50 ml U ml—1)
detected in serum or cerebrospinal fluid (CSF) were eligible since
germinomatous tumours may present with a moderate secretion
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Sutton, Surrey SM2 5PT, UKwhen they contain scattered syncytiotrophoblastic giant cells
(Mostofi et al, 1988; Munperow et al, 1992). For these patients with
moderate secretion, histological confirmation of germinoma was
recommended but not compulsory. Six patients presenting with
pineal (two patients), suprasellar (three patients) or bifocal (one
patient) tumour with negative markers and without histological
diagnosis are detailed separately. Initial staging procedure included
clinical examination, assessment of tumour markers in the serum
and/or the CSF, review of the operative notes, postoperative cranial
computed tomography (CT) or magnetic resonance imaging (MRI)
scan, myelogram or MRI scan of the spine and cytological CSF
examination.
After diagnosis, patients were given four courses of chemo-
therapy. The regimen was administered as follows: Courses 1 and
3: carboplatin (600 mg m—2) on day 1; etoposide (150 mg m—2 day—1)
from days 1 to 3; Courses 2 and 4: ifosfamide (1.8 g m—2 day—1)
from days 21 to 25 and etoposide (150 mg m—2 day—1) from days 21
to 23. Response was assessed after two courses by repeating those
diagnostic tests that originally identified the evaluable disease.
After the four courses of chemotherapy, radiation therapy was
administered to the initial tumour volume, at a daily dose of 1.8 Gy
with 5 weekly fractions up to a recommended dose of 40 Gy deliv-
ered over 4.5 weeks. Radiotherapy guidelines recommended using
a linear accelerator of 4.6 or 9 MeV with at least two parallel
opposed fields. The recommended safety margins were 2 cm
around the initial tumour. In case of disseminated germinoma,
craniospinal radiotherapy was added to the protocol. The recom-
mended dose to the brain and the spine was 25—30 Gy with a
10 Gy boost on metastatic deposits. However, local rather than
craniospinal radiotherapy was recommended for patients with
non-metastatic bifocal tumours.
All patients were followed clinically during and after treatment.
CT or MRI scan of the head with and without administration of
contrast material, was obtained 2 months after the completion of
the radiotherapy, and then every 4 months during the first 2 years
unless additional examinations were indicated clinically. The
scans were then repeated at 6-monthly intervals. Because origi-
nally non-secreting patients may relapse with aFP and/or bHCG
secretion (Ono et al, 1994), tumour markers were regularly
checked. Progression was defined as any new lesion detected in
any of the examinations with or without elevation of tumour
markers. A complete restaging (CSF examination, CT scan or
MRI of the brain, and MRI scan of the spine, tumour markers) was
performed for relapsing patients.
RESULTS (Table 1)
Between January 1990 and December 1996, 99 newly diagnosed
patients from 25 centres were enrolled in the SFOP protocol for
intracranial GCTs. Fifty-nine were registered in the germinoma
study. Other patients were registered in the non-germinomatous
intracranial GCT study. Patients with a biopsy-proven germinoma
associated with high bHCG secretion and/or aFP secretion were
allocated to the latter study group. Out of the group of 59 patients
with germinomas, two non-metastatic patients received chemo-
therapy followed by craniospinal radiotherapy due to physician
decision and are not included in this report. Fifty-seven patients
treated according to the SFOP protocol are reported here. Forty-
seven of them were included on the basis of histological diagnosis.
Ten were treated without having a biopsy either because of a
moderate elevation of bHCG (less than 50 ml U/ml, four patients)
or because the neurosurgeon was reluctant to perform a biopsy (six
patients). Six patients had metastatic disease at presentation: two
presented with positive CSF cytology (assessed by lumbar punc-
ture), two had spinal metastases and two had diffuse periventric-
ular seeding.
The median age was 13.5 years (range 50 months to 22 years).
There were 43 males and 14 females. Fifty patients had unifocal
lesions, the site of origin of the tumour being suprasellar in 20,
pineal in 28, thalamic in two. Seven patients had bifocal tumours,
which in all combined a suprasellar and a pineal mass. These
patients — apart from one with concomitant spinal deposits — were
not considered as metastatic and received the treatment for non-
metastatic patients. Twenty-nine patients with biopsy-proven
localized germinoma have been the subject of a preliminary
analysis (Baranzelli et al, 1997).
Surgery
Forty-seven patients had surgery. This was limited to a stereotactic
biopsy in 22 patients or an open biopsy in seven. Eighteen patients
had a more aggressive surgery with either partial (12 patients) or
total (six patients) resection.
Chemotherapy administration and response
Fifty-two patients received four courses of chemotherapy
according to the protocol. One patient developed severe toxicity
after the first course and chemotherapy was therefore suspended.
He consequently received conventional craniospinal radiotherapy
instead of local radiotherapy. Four patients had protocol deviations
and received five, eight, nine and 12 courses of chemotherapy,
respectively. Response to chemotherapy was reported after two
and four courses in 38 out of 51 evaluable patients who started
chemotherapy with an assessable mass. All patients responded.
Following four courses, complete response was observed in 18
patients, and 20 patients demonstrated residual abnormalities,
mainly mild focal enhancement or calcified debris. None of these
patients had second surgery on the residue.
Radiotherapy was given according to the protocol in 55 patients.
The median time from diagnosis to the starting day of radiotherapy
was 107 days (range 88—159 days) for those patients who received
four courses of chemotherapy. The six patients with metastatic
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Table 1 Patients’ characteristics
Number of patients 57
Male 43
Female 14
Age at diagnosis
Median 13.5
Range 4.1–22
Tumour location
Pineal 20
Suprasellar 28
Thalamic 2
Bifocal 7
Leptomeningeal disease at diagnosis 6
Diagnostic procedure
Resection 18
Biopsy 29
Tumour marker only 4
None 6
bHCG secretion 9germinoma received craniospinal radiotherapy, and one patient
received craniospinal radiotherapy due to severe toxicity after one
course of chemotherapy. Forty-eight patients received local treat-
ment using conventional radiotherapy at a median dose of 40 Gy.
Eight patients received a dose greater than 40 Gy to the primary.
One patient with congenital panhypopituitarism received stereo-
tactic radiotherapy.
Toxicity
The median interval between courses ranged from 23 days (18—51
days) for cycle 1 to 24 days (19—41 days) for cycle 3. Data on
haematopoietic toxicity are available for 230 courses. Grade 3 or 4
WHO toxicity (platelet count < 50 ´ 109 l—1 and/or neutrophil count
< 0.5 ´ 109 l—1) occurred in 106 courses, and was similar following
either the carboplatin-containing courses (56 episodes) or the ifos-
famide containing ones (50 episodes). Six patients had bacterial
septicaemia, one episode occurring after course 1, leading to
cessation of chemotherapy.
The major non-haematopoietic toxicity was electrolyte imbal-
ance during courses 1, 2 and 4 in patients with diabetes insipidus.
All patients with diabetes insipidus (n = 25) experienced elec-
trolyte disturbances, which required prolonged hospitalization in
five patients following course 1, five patients following course 2
and two patients following course 4. Four patients presented with
grade 3 neurological toxicity during ifosfamide administration.
Grade 2—3 gastrointestinal toxicity, including abdominal pain and
diarrhoea, was reported in 11 courses. No toxic death occurred
during chemotherapy or radiotherapy.
Outcome (Figure 1)
The median follow-up time for the 57 patients was 42 months
(range 6—90 months). The estimated 3-year survival probability
is 98% [confidence interval (CI): 86.6—99.7%] and the estimated
3-year event-free survival is 96.4% (CI: 86.2—99.1%). Overall and
event-free survival are shown in Figure 1. No patient experienced
treatment failure while on therapy. Four patients developed tumour
recurrence 9, 10, 38 and 57 months after diagnosis. Two patients
had raised bHCG at the time of recurrence, including one who had
no tumour marker at the time of diagnosis. All recurrences had at
least an intracranial component, involving the trigone and the cere-
bellum in one patient, the third ventricle in the second, the pineal
area in the third, and the pineal area and the lateral ventricle in the
last patient. One initially metastatic patient had a spinal deposit on
the MRI scan. Cytological examination of the CSF was positive
in another patient. Salvage therapy was given at the time of
recurrence in all patients. One achieved transient response to
a cisplatin—ifosfamide—etoposide combination but ultimately
progressed and died 6 months post-recurrence. One patient was
retreated with an etoposide—carboplatin combination followed by
craniospinal radiotherapy. He is currently in second complete
remission, 22 months post-recurrence. Two patients achieved
second remission with a cisplatin—ifosfamide—etoposide combina-
tion. They subsequently received high-dose chemotherapy
followed by peripheral stem cell transplants, and are in second
complete response 8 and 24 months post-recurrence, respectively.
Overall, three patients with initial localized disease relapsed and
achieved second remission. One metastatic patient relapsed and
died of disease. No recurrence was observed among non-
metastatic patients with bifocal tumours.
Outcome of patients who did not have surgery at the
time of diagnosis
Ten patients did not undergo initial surgery. Nine received four
courses of chemotherapy, and one received five courses. The four
patients with raised bHCG all achieved biological remission after
one course of chemotherapy. CT or MRI scan assessment after
four courses showed complete response in seven patients and
partial response in three. Radiotherapy was given as per protocol
in all patients. Two patients relapsed. One had a loco-regional
relapse (pineal area and trigone) 10 months post-diagnosis. He
underwent a biopsy, which confirmed the diagnosis of germinoma.
He achieved complete remission following chemotherapy and
craniospinal radiotherapy and is currently free of disease 22
months post recurrence. The second patient initially had low-level
secretion of bHCG. He relapsed in the cerebellum and the trigone
57 months post-diagnosis. He achieved complete remission after
four courses of a cisplatin—ifosfamide—etoposide regimen and then
received high-dose chemotherapy with stem cell rescue. He is
currently in complete remission 8 months after recurrence.
DISCUSSION
Despite achievement of high cure rates, the current management
of intracranial germinomas remains controversial (Oi et al, 1992;
Matsutani et al, 1997). Several aspects of the management differ
between institutions or national groups. Surgery as an initial
procedure is strongly supported by the majority of neurosurgeons
in America and Europe, but numerous Asian and African institu-
tions still favour the ￿radiotherapeutic test￿ (Oi et al, 1992).
Craniospinal radiotherapy is still the standard treatment for many
centres, but some radiotherapists favour local radiotherapy and
oncologists are increasingly interested in giving chemotherapy in
order to reduce either the dose or the extent of radiotherapy. The
SFOP group has prospectively explored the feasibility of a
combined approach that can be compared to other prospective
multicentre trials such as the MAKEI trials (Gobel et al, 1989,
1993) and the First International Central Nervous System Germ
Cell Tumor Study (Balmaceda et al, 1996).
In germinoma, there is little evidence that the extent of surgery
influences the outcome. Reports that favour radical surgery
combine in their analysis germinomas and non-germinomatous
GCTs (Matsutani et al, 1997). In our series, all four relapses
occurred in patients who had either incomplete resection or no
surgery. However, only six patients had complete removal of their
Combined treatment modality for intracranial germinomas 1201
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Figure 1 Event-free (– – –) and overall (–––) survivaltumour and the low incidence of recurrences (four out of 51 who
had residual disease at initiation of chemotherapy) does not
support a role for aggressive debulking. Sawamura et al (1997)
advocated limited biopsy in germinomas, which provides suffi-
cient information for diagnosis and treatment planning. Some
patients may present with a slight isolated elevation of HCG or
bHCG in serum and/or CSF of below 50 ml U ml. Such levels are
highly suggestive of germinomas with syncytiotrophoblastic cells
(Uematsu et al, 1992; Shibamoto et al, 1997). For these patients a
diagnostic biopsy is questionable given the theoretical risk of
morbidity resulting from surgical procedures. In our series, four
out of nine patients who presented with a slight isolated elevation
of HCG had no histological diagnosis and their tumour evolved in
the same manner with the same treatment. Moreover, six patients
were treated on imaging criteria without either histological proof
or any elevation of bHCG favouring the diagnosis of germinoma
with syncytiotrophoblastic cells. In each of these cases, biopsy
was not performed because of concerns of the neurosurgeon. The
decision to include patients without histological diagnosis in our
final analysis may be controversial. However, all these patients did
respond to chemotherapy and all but two achieved long-term
remission with the treatment plan. One patient underwent a biopsy
at the time of relapse, which ultimately confirmed the diagnosis of
germinoma. A ￿chemotherapeutic test￿ for patients with a high risk
of surgical morbidity is, in our experience, a successful alternative
to the ￿radiotherapeutic test￿. One may hope that detection of
sensitive and specific tumour markers for germinomas will
contribute to non-invasive diagnosis (Shinoda et al, 1988). Some
authors have suggested that intracranial germinoma with syn-
cytiotrophoblastic giant cells producing HCG is associated with a
higher recurrence rate compared with pure germinoma (Uematsu
et al, 1992; Shibamoto et al, 1997). Only one patient relapsed in
the group of nine who had slight elevation of HCG. This might
suggest that highly effective treatment can mask this adverse prog-
nostic feature, or that this group needs a longer follow-up to draw
definite conclusions, since late recurrences have been reported
with this entity.
Using craniospinal radiotherapy, the survival rate in large series
ranges between 75 and 95%. These good results have provided the
rationale for a systematic approach using craniospinal radio-
therapy in all patients, regardless of their metastatic status.
However, this treatment was developed at a time when staging
procedures were limited, and it was therefore a safe option for
unstaged patients. With modern imaging procedures, the propor-
tion of patients presenting with metastatic disease at the time of
diagnosis is low, and the risk of secondary spinal seeding in germi-
noma does not exceed 15% in large series (Sung et al, 1978;
Linstadt et al, 1988; Matsumani et al, 1997). Furthermore, in a
review of the literature, Brada et al (1990) have shown that the
incidence of secondary seeding did not differ between patients
treated with craniospinal radiotherapy and whole brain radio-
therapy. The benefit of craniospinal radiotherapy thus seems ques-
tionable (Linstadt et al, 1988). Recent studies have suggested that
reduced doses of prophylactic craniospinal radiotherapy are effec-
tive (Hardenbergh et al, 1997; Plowman et al, 1997). Single insti-
tution experiences have shown that, with complete diagnostic
craniospinal evaluation, spinal irradiation is not necessary and
cure rates for localized germinomas are excellent with focal irradi-
ation (Wolden et al, 1995; Sawamura et al, 1998). When focal
radiotherapy is advocated, the dimension of the field is another
matter of debate. Some authors recommend irradiation to a
generous local field encompassing the tumour site for localized
germinomas (Dattoli et al, 1990; Shibamato et al, 1994). For other
authors, the local field should include the third and lateral ventri-
cles as well as the sellar and the pineal region (Matsuani et al,
1997; Shirato et al, 1997). New techniques such as radiosurgery or
stereotactic radiotherapy have been proposed (Manera et al, 1996).
The optimal dose of radiotherapy to the tumour bed is still unclear.
Most authors recommend 40 Gy, but some authors consider that
50—60 Gy is the adequate dose for this tumour, leading to better
local control (Wolden et al, 1995; Haddock et al, 1997). In our
experience, all recurrences had an intracranial component, and this
could argue for a larger field or higher doses of radiotherapy. The
small number of failures with our present approach and the risk of
increased morbidity with larger fields or higher doses of radio-
therapy in this young population point out the difficulty of
achieving a consensus. Conversely, the dose of 40 Gy proposed in
the present protocol could perhaps be reduced. This choice was
deliberate following the disappointing results observed in a
previous SFOP study using a 30 Gy boost to the tumour bed
(Calaminus et al, 1994). The chemotherapy regimen in this latter
protocol was, however, significantly different and definitely less
effective. Our series shows that chemotherapy followed by local
radiotherapy delivered to the initial tumour volume is a safe alter-
native to craniospinal radiotherapy or whole ventricle irradiation.
Long-term effects of craniospinal radiotherapy are well known,
and mainly affect young children. Those who favour craniospinal
radiotherapy argue that patients with germinoma are older than
patients with medulloblastoma, and neuropsychologic distur-
bances or spinal growth alterations seem to be less marked in this
age range (Kiltie et al, 1995). However, eighteen out of 57 children
in our series were less than 12 years old but 11 additional children
above 12 years of age presented with either isolated growth
hormone deficiency or panhypopituitarism and, therefore, short
stature at the time of diagnosis. The risk of short stature following
craniospinal radiotherapy has consequently to be regarded as an
important issue regardless of the age at presentation.
We favoured a combination of chemotherapy and local radio-
therapy for patients with localized germinomas. Platinum
compounds are effective in intracranial GCTs, with high response
rates reported in germinoma and non-germinomatous tumours
using cisplatin or carboplatin (Kobayashi, 1989; Patel et al, 1992;
Allen et al, 1994). The carboplatin—etoposide association has
demonstrated impressive response rates in embryonal tumours of
the CNS (Gentet et al, 1994; Heideman et al, 1995). Ifosfamide is a
cyclophosphamide analogue, which is commonly used for poor risk
extracranial GCTs (Roth, 1996). Cyclophosphamide has shown
promising activity in intracranial GCTs, particularly in germinomas
with 100% responses among 11 newly diagnosed patients in the
pilot study reported by Allen et al (1985, 1987). Data on ifosfamide
efficacy in intracranial GCTs are few, but this drug has shown
excellent CSF diffusion (Ninane et al, 1989). In our experience, all
assessable patients achieved at least partial response after two
courses of chemotherapy, but no specific conclusion can be made
from the etoposide—ifosfamide combination. It is noteworthy that
bleomycin was not used in this study. The toxicity of this agent,
particularly in children, and the lack of data on its efficacy in
intracranial GCTs have precluded its use in our study. The response
rate to chemotherapy is excellent since all patients with evaluable
disease achieved either partial or total response after chemotherapy.
The toxicity of this regimen is limited, and no patient died from
a chemotherapy-related complication. Apart from haematological
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insipidus, which occurred in all patients with replacement therapy.
These patients might benefit from the administration of aqueous
vasopressin by continuous infusion to control the fluid and elec-
trolyte balance as previously reported (Bryant et al, 1994). Only
one patient developed life-threatening infection leading to interrup-
tion of chemotherapy. By contrast, the first international CNS
GCT study group, using an intensive carboplatin—etoposide and
bleomycin combination, has reported significant regimen-associ-
ated morbidity and mortality (Balmaceda et al, 1996). The aim of
that protocol was different, in trying to avoid radiotherapy for
responding patients. There, half of the 45 germinoma patients
achieved long-term remission without radiotherapy, but 22 required
salvage treatment including extensive radiotherapy and/or high-
dose chemotherapy for some patients. Seven patients died, four
from toxicity and three from progression. No prognostic factor was
identified that could distinguish the group of patients who required
only chemotherapy. In our study, all patients were given radio-
therapy, regardless of their response to chemotherapy. Since
chemotherapy has been shown to be effective in intracranial germi-
noma, the decision to irradiate responding patients may be debat-
able. The difference in terms of tumour control between
chemotherapy alone and chemotherapy followed by focal radio-
therapy favours the second option. The low progression rate in our
report is qualified by a short follow-up in a disease where late
recurrences are not uncommon (Ono et al, 1994). However, the
42-month follow-up for the whole group does not differ from other
large prospective series (Gobel et al, 1993; Balmaceda et al, 1996).
Chemotherapy in our experience did allow avoidance of prophyl-
actic craniospinal radiotherapy in patients with localized germi-
nomas. Four patients relapsed, including two with spinal seeding.
One initially non-secreting patient had elevated bHCG at recur-
rence, which compares to previous reports on recurrent intracranial
germinomas (Ono et al, 1994; Balmaceda et al, 1996). The failure
rate is low (7%) and three patients achieved complete remission
following salvage treatment. Only one patient, who had metastatic
disease at presentation, died from disease progression. The 3-year
event-free survival (96%) and the overall survival (98%) compare
favourably with results from other series.
The long-term side-effects of carboplatin, ifosfamide and etopo-
side are well described. The main potential issue of this protocol
concerns fertility in males and the risk of secondary leukaemia.
The cumulative doses of ifosfamide and etoposide are 18 g m—2 and
1800 mg m—2, respectively. The risk of ifosfamide-associated infer-
tility in males is still poorly documented and more follow-up is
required to know whether such a dose leads to gonadal late effects.
The risk of secondary etoposide-induced leukaemia is dose-depen-
dent and most of the cases reported previously occurred with
cumulative doses above 2 g m—2 (Smith et al, 1994). However, this
risk has been considered in the design of future studies and the
forthcoming SFOP protocol is planned with a reduced cumulative
dose of 1.2 g m—2 of etoposide. In this series, the follow-up is too
short to assess the fertility in survivors, and no patient has devel-
oped secondary malignancy. The fertility question is complicated
by the high incidence of tumour- or surgery-induced pituitary
damage, especially among patients with suprasellar germinomas.
In this series, patients have been arbitrarily divided in two
groups: those with genuine metastatic disease (six patients), and
those with bifocal lesions (seven patients, one patient having a
bifocal lesion with metastatic deposits). Low-dose craniospinal
radiotherapy after chemotherapy led to prolonged remission in five
out of six patients with genuine metastatic disease. Local radio-
therapy to the primary site led to 100% control in patients with
non-metastatic bifocal lesions. This suggests that bifocal lesions
may be considered as loco-regional disease rather than metastatic,
and that the need for craniospinal radiotherapy can be limited to
those patients with spinal seeding only. This points out the impor-
tance of the initial staging, including CSF cytology and MRI scan
of the spine, when treatment modalities vary according to the
extent of the disease.
Management in intracranial germinoma benefits from the
chemo- and radiosensitivity of this tumour. For decades, paediatric
neuro-oncologists have been looking for alternatives to
craniospinal radiotherapy in malignant brain tumours. While
craniospinal radiotherapy is still a prerequisite for cure in medul-
loblastoma, in germinoma chemotherapy can be utilized to achieve
dose and field reduction. One may question whether local radio-
therapy only should be an alternative to combined chemo-radio-
therapy. Information on this issue is limited and ultimately only
randomized studies comparing chemotherapy combined with
radiotherapy to local radiotherapy alone will answer this question.
The dose of radiotherapy and the extent of the fields are other
important issues. The 40 Gy dose might be reduced as well as the
volume irradiated, considering the frequent massive shrinkage
observed after chemotherapy in germinomas. Oncologists have
two treatment modalities that achieve the same excellent survival
rate. Long-term follow-up studies reporting on quality of life for
survivors are required to draw definite conclusions on the optimal
management with minimum side-effects.
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